Exhibit 99.1 Bristol Myers Squibb Reports Second Quarter Financial Results for 2025 Performance Underscores Continued Execution Against Long-Term Growth Strategy (PRINCETON, N.J., July 31, 2025) – Bristol Myers Squibb (NYSE: BMY) today reports results for the second quarter of 2025. "We are making good progress rewiring the company for long-term growth. In the second quarter, we delivered strong results across our Growth Portfolio, continued to optimize our cost structure, and added to our innovative pipeli ...

百时美施贵宝预计全年调整后每股收益6.35美元至6.65美元。 百时美施贵宝预计全年营收465亿美元至475亿美元。 第二季度调整后每股收益1.46美元。 百时美施贵宝第二季度营收122.7亿美元，预估113.8亿美元。 ...

CHONGQING, CHINA - JULY 29: In this photo illustration, a person holds a smartphone displaying the ... More logo of Bristol Myers Squibb Company (NYSE: BMY), a global biopharmaceutical firm focused on oncology, immunology, and cardiovascular diseases, with the company's purple hand-shaped branding visible in the background, on July 29, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images) Getty Images Bristol Myers Squibb (NYSE:BMY) is scheduled to release its earnings report on Thursday, ...

Core Insights - Bristol Myers (BMY) has partnered with Bain Capital to establish a new independent biopharmaceutical company focused on developing therapies for autoimmune diseases, addressing significant unmet patient needs [1][9] - Bain Capital will invest $300 million in the new company, while BMY will out-license five immunology candidates and retain a nearly 20% equity stake [1][3][9] Summary by Categories Company Developments - The new company will focus on autoimmune disease therapies, with BMY out-licensing five immunology candidates, including three clinical stage candidates and two phase I-ready candidates [2][3] - The most advanced assets include afimetoran, an oral TLR7/8 inhibitor in phase II for systemic lupus erythematosus (SLE), and BMS-986322, an oral TYK2 inhibitor with positive phase II results for plaque psoriasis [2] Financial Aspects - BMY will earn royalties and milestones based on the success of each asset in the new company [3][9] - BMY's shares have decreased by 17.2% year-to-date, contrasting with the industry growth of 0.6% [7][8] - BMY is trading at a price/earnings ratio of 7.59x forward earnings, lower than its historical mean of 8.51x and the large-cap pharma industry's 15.11x [10] Market Competition - BMY faces competition in the immunology space, particularly with its drug Sotyktu competing against Amgen's Otezla in psoriasis [5] - In oncology, BMY competes with major players like Merck, whose Keytruda dominates the immuno-oncology market [6] Future Estimates - The bottom-line estimate for 2025 has been revised down to $6.33 from $6.76 over the past month, with a slight decline in the 2026 estimate as well [11]

1. AbbVie Many have scrutinized the drug industry, often for good reasons. However, medicine remains a core pillar of the broader healthcare sector, and that probably won't change anytime soon, if ever. AbbVie (ABBV 1.45%) is one of the world's prominent biopharmaceutical companies. It has a robust portfolio of drugs used to treat over 75 conditions, with core focuses in immunology, neuroscience, oncology, aesthetics, and eye care. Being a great investor doesn't have to be complicated or expensive. Often, g ...

Summary of Key Points from the Conference Call Industry Overview - The Chinese innovative pharmaceutical industry is experiencing a significant enhancement in strength, with its share of global first-in-class drugs increasing to 19% [7] - Multinational corporations (MNCs) are facing a severe patent cliff, with major companies like Merck, AbbVie, and BMS having over 60%, 58%, and 69% of their 2024 revenues coming from drugs facing patent expiration within the next five years [8][9] - MNCs are actively seeking business development (BD) transactions to address these challenges, with strong cash reserves available for such activities [10] Business Development Trends - The trend of Chinese innovative drugs going global is robust, driven by the strengthening capabilities of Chinese companies and the impending patent cliffs faced by MNCs [2] - MNCs are expected to engage in more BD transactions, particularly in the second half of 2025 and into 2026, as they seek to replenish their pipelines [2] Oncology Sector Insights - The oncology field is shifting from PD-1 combined with chemotherapy to next-generation immuno-oncology (IO) and antibody-drug conjugates (ADC) [3] - Potential MNC buyers in this space include AstraZeneca, Pfizer, and Merck, all of which are looking to enhance their portfolios with next-generation IO and ADC assets [3] Metabolic Disease Developments - The metabolic field is evolving from merely focusing on weight loss to comprehensive metabolic management, including fat reduction and muscle preservation [4][5] - Companies like Novo Nordisk and AstraZeneca are exploring oral medications and multi-target approaches in this area [4] Immune and Inflammatory Disease Innovations - New directions in the immune and inflammation sector include novel targets and engineering innovations, with significant investments from companies like AbbVie and Sanofi [6] - Emerging targets such as TL1a are attracting substantial investments, indicating a strong interest in this area [20] Market Position of Chinese Innovative Drugs - Chinese innovative drug companies have made significant strides in global markets, with improved clinical data quality and increased academic recognition [7] - The presence of Chinese companies in the oncology sector is growing, with several projects in advanced stages of development [14] MNC Strategies for BD Transactions - MNCs are focusing on four main strategies for BD transactions: consolidating core areas, entering new fields, exploring opportunities, and investigating new technologies [11] - The willingness of MNCs to invest in promising assets at the preclinical stage is evident, particularly in high-potential areas like TL1a [20] ADC and TCE Technology Developments - The ADC field is characterized by a tiered approach, with MNCs diversifying their portfolios across various targets [15] - T-cell engagers (TCE) are being developed for blood cancers and autoimmune diseases, with ongoing clinical trials showing promising results [16] Conclusion - The ongoing trends in the Chinese pharmaceutical industry, coupled with the challenges faced by MNCs, are creating a fertile ground for increased collaboration and investment opportunities in the global market [29]

Group 1 - Bristol-Myers Squibb (BMY) and Bain Capital announced the formation of a new independent biopharmaceutical company focused on developing therapies for autoimmune diseases [1] - The new company will initially possess five immunology assets acquired from Bristol-Myers Squibb and has secured a $300 million financing commitment primarily from Bain Capital [1] - The research pipeline includes three drugs in clinical trials and two drugs entering early research stages, all targeting mechanisms related to autoimmune diseases [1] Group 2 - Core assets include afimetoran, an oral drug currently in mid-stage clinical trials for systemic lupus erythematosus, and BMS-986322, which has shown positive results in mid-stage trials for plaque psoriasis [1] - According to the collaboration agreement, Bristol-Myers Squibb will retain nearly 20% equity in the new company and will receive royalties and milestone payments based on the development and commercialization success of these assets [1] - The Canadian Pension Plan Investment Board is also participating in this investment [1] Group 3 - Bristol-Myers Squibb is betting on a series of new drugs to compensate for the declining sales of its legacy blockbuster drugs [2] - The company's best-selling cancer immunotherapy drug Opdivo is expected to face pricing pressure before 2030, while its blood thinner Eliquis will face generic competition by 2028 [2] Group 4 - As of the latest update, the company's stock rose by 0.29% in after-hours trading [3]

Industry Overview - The second-quarter 2025 reporting cycle for the Medical sector is commencing, with most firms expected to release earnings results in the next two weeks, primarily consisting of pharma/biotech and medical device companies [1] - The earnings season for the drug and biotech sector began in mid-July, highlighted by Johnson & Johnson's strong performance, which exceeded earnings and sales estimates, leading to raised revenue and earnings expectations for the year [1] Company Performance - Novartis surpassed second-quarter earnings and revenue estimates, driven by a year-over-year increase in sales of key drugs, prompting an upward revision of its annual guidance for core operating income [2] - Roche experienced solid growth in the first half of 2025, with high demand for key drugs offsetting declines in legacy drug sales [2] - As of July 23, 15% of companies in the Medical sector, representing 27.2% of the sector's market capitalization, reported quarterly earnings, with 88.9% outperforming earnings estimates and 100% beating revenue estimates [3] - Overall, second-quarter earnings for the Medical sector are projected to increase by 0.9%, while sales are expected to rise by 7.9% compared to the previous year [3] Upcoming Earnings Reports - Merck, AstraZeneca, Bristol Myers, AbbVie, and Moderna are scheduled to release their quarterly results this week [4] - Merck has a strong earnings track record, beating estimates in the last four quarters with an average surprise of 3.82% [5] - AstraZeneca has a mixed earnings history, beating estimates in three of the last four quarters, with an average surprise of 4.24% [8] - Bristol Myers has consistently beaten earnings estimates, with an average surprise of 20.16% over the last four quarters [11] - AbbVie has also maintained a strong track record, beating estimates in the last four quarters with an average surprise of 2.55% [13] - Moderna has an excellent earnings history, with an average surprise of 31.60% in the last four quarters [15] Sales Drivers - Merck's growth in the second quarter is likely attributed to increased sales of its cancer drug Keytruda, driven by additional indications and patient demand [7] - AstraZeneca's sales are expected to be bolstered by strong demand for its cancer and diabetes medications [10] - Bristol Myers' revenue may be impacted by declines in legacy drug sales, but growth products are expected to partially offset this decline [12] - AbbVie's revenue is anticipated to be driven by strong sales of key drugs and contributions from newer products [14] - Moderna's revenues are expected to be influenced by sales of its COVID-19 vaccine, Spikevax, while the focus is shifting to updates on its broader pipeline [16]

Core Viewpoint - Bristol-Myers Squibb Company (BMY) is set to report its second-quarter 2025 results on July 31, with sales and earnings estimates at $11.38 billion and $1.18 per share, respectively. However, earnings estimates for 2025 and 2026 have seen a decline over the past month [1][5]. Financial Estimates - The current earnings estimate for Q2 2025 is $1.18, down from $1.55 30 days ago, reflecting a decrease of 29.34%. The earnings estimates for 2025 and 2026 have also decreased to $6.37 and $6.03, respectively [2][5]. - BMY has a strong earnings surprise history, beating estimates in the last four quarters with an average surprise of 20.16% [2]. Factors Influencing Q2 Results - Total quarterly revenues are expected to be negatively impacted by declining sales from the legacy portfolio, which includes drugs like Eliquis, Revlimid, and Pomalyst, primarily due to generic competition [4][5]. - Sales for Pomalyst are estimated at $727 million, while Eliquis is projected to generate $3.5 billion in sales [6][7]. Growth Portfolio Performance - The growth portfolio, which includes drugs like Opdivo, Reblozyl, and Camzyos, is expected to partially offset the decline in legacy drug sales. Opdivo sales are estimated at $2.4 billion, while Reblozyl is projected at $546 million [8][10][11]. - New drug Cobenfy for schizophrenia has shown promising sales growth, indicating a positive start for the newly launched product [12][18]. Strategic Initiatives - BMY has announced cost-cutting plans aiming to save $1.5 billion by 2025 and an additional $2 billion annually by 2027, which are expected to improve profitability [5][14]. - The company has entered a strategic collaboration with BioNTech for the co-development of a bispecific antibody, BNT327, which targets solid tumors [19][22]. Stock Performance and Valuation - BMY shares have declined by 14.4% year-to-date, underperforming the industry and the S&P 500 [16]. - The stock currently trades at a price/earnings ratio of 7.84x forward earnings, lower than its historical mean and the large-cap pharma industry average [20].

智通财经7月28日电，智通财经从百时美施贵宝获悉，其欧狄沃（纳武利尤单抗注射液）联合逸沃（伊 匹木单抗注射液）方案获国家药品监督管理局（NMPA）批准，适用于由国家药监局批准的检测评估为 PD-L1肿瘤比例分数（TPS）≥1%的表皮生长因子受体（EGFR）基因突变阴性和间变性淋巴瘤激酶 （ALK）阴性的转移性非小细胞肺癌一线治疗。该联用疗法是中国首个获批的肺癌双免疫联合疗法， 为前述适应证患者提供了无化疗的长生存新选择。 (智通财经记者 陈杨) 百时美施贵宝获批中国首个非小细胞肺癌一线双免疫疗法 ...